Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

This publication has 17 references indexed in Scilit:

• The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications
  Metabolism, 2000
• The Importance of Diagnosing the Polycystic Ovary Syndrome
  Annals of Internal Medicine, 2000
• Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)
  Clinical Endocrinology, 2000
• Increased Frequency of Genetic Thrombophilia in Women with Complications of Pregnancy
  New England Journal of Medicine, 1999
• Antepartum Testing
  Clinical Obstetrics and Gynecology, 1998
• Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
  Fertility and Sterility, 1998
• Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndrome
  Clinical Endocrinology, 1996
• Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
  Metabolism, 1994
• The management of non-insulin-dependent diabetes during pregnancy
  Diabetes Research and Clinical Practice, 1986
• Metformin in management of pregnant insulin-independent diabetics
  Diabetologia, 1979